Clinical protocols for high-sensitivity troponin testing at Emory University Orthopedics and Spine Hospital (EUOSH) – go-live date Sept. 22, 2021

Emory and Grady HS troponin clinical protocols working group
Laboratory Medicine: Janetta Bryksin, PhD
Cardiology: Abhinav Goyal, MD; Michael McDaniel, MD; Michael Balk, MD; Matthew Topel, MD
Emergency Medicine: Michael Ross, MD; George Hughes, MD; Matthew Wheatley, MD; Sofia Khan, MD
Hospital Medicine: Ingrid Pinzon, MD; Viniya Patidar, MD
Project Manager: Shannon Lauer, MHA, PMP

* Disclaimer: The high-sensitivity troponin I protocol in these slides have been developed *only* for Emory University Orthopedics and Spine Hospital which uses the Beckman Coulter Access 2 Immunoassay analyzer. The troponin cut points in these slides do *not* pertain to Emory University Hospital, Emory University Hospital Midtown, Emory Saint Josephs Hospital, Emory Johns Creek Hospital, Emory Decatur Hospital, Emory Hillandale Hospital, Emory Long-Term Acute Care hospital, and Grady Memorial Hospital, which use different lab analyzers (refer to separate protocols).

References:
1. Thygesen K et al. Fourth Universal Definition of MI (2018). J Am Card Cardiol 2018
2. Collet JP et al. 2020 ESC Guidelines for management of ACS in patients without persistent ST-segment elevation. Eur Heart J 2020. doi: 10.1093/eurheartj/ehaa575
3. Beckman Coulter UniCel DxI Access analyzer package insert (2020).
4. Apple FS et al. Getting cardiac troponin right. Clin Chem 2021. doi: 10.1093/clinchem/hvaa337
5. Boeddinghaus J et al. HS cardiac troponin I assay for early diagnosis of AMI. Clin Chem 2019. doi: 10.1373/clinchem.2018.300061
6. Januzzi JL et al. Recommendations for institutions transitioning to HS troponin testing. J Am Card Cardiol 2019. doi: 10.1016/j.jacc.2018.12.046

Inquiries:
Abhinav Goyal, MD, MHS, FACC, FAHA
Professor of Medicine, Emory University School of Medicine
Prof. of Epidemiology, Emory Rollins School of Public Health
Chief Quality Officer, Emory Heart and Vascular Center
Atlanta, GA, USA Email: ABHINAV.GOYAL@EMORY.EDU

For all Emory HS troponin clinical protocols and videos, visit:
https://med.emory.edu/departments/medicine/divisions/cardiology/hs-troponin-protocols/index.html
For Emory HS troponin educational video, visit:
https://youtu.be/v0muP7bveYM

Version: August 31, 2021

Background

- Europe has been using high-sensitivity troponin testing (hs-Tn) for >5 years; U.S. hospitals in various stages of adopting hs-Tn testing

- High sensitivity troponin test is more sensitive, & more precise at low concentrations, than standard troponin

- High-sensitivity troponin testing allows for faster MI “rule outs” in chest pain patients presenting to the ED
  - This leads to more efficient ED throughput

- Tradeoff: hs-Tn less specific for treatable heart attacks (e.g. Type 1 NSTEMI), and instead detects all types of heart injury (including nonischemic myocardial injuries and Type 2 MI), that don’t necessarily warrant treatment or change management

Equivalency of values: TnI vs. hs-TnI (EUOSH) *

Note the following differences between standard troponin I and high-sensitivity troponin I (hs-TnI):

1. Units of measurement are different. hs-TnI is reported **as integers in ng/L** (whereas TnI was in ng/mL)
2. To convert from hs-TnI to standard TnI (for clinical context), **divide by 1000**. Example: hs-TnI value of 100 ng/L corresponds to a standard TnI value of 0.1 ng/mL. See table below.
3. hs-TnI has different "abnormal" cut point, (or 99th percentile value) in women and men.

These TnI values are reported as < 0.03 ng/mL

standard TnI (ng/mL)	**hs-TnI** (ng/L)	**Notes**
0.002	< 2.0	LOQ** for hs-TnI
0.012	12	99 percentile (abnormal) hs-TnI value for women
0.02	20	99 percentile (abnormal) hs-TnI value for men
0.03	30	
0.04	40	99 percentile (abnormal) standard TnI value
0.05	50	
0.1	100	
0.5	500	
1	1000	
10	10000	
25	> 25000	Highest reportable value of analytic range for hs-TnI
>70		Highest reportable value of analytic range for TnI

* EUOSH uses a Beckman Coulter Access 2 Immunoassay analyzer with the following "abnormal" (>99th percentile) cut points: >11.6 mg/L in women; >19.8 ng/L in men. These cut points do NOT apply for EUH, EUHM, ESJH, EJCH, EDH, EHH, ELTAC , or Grady Memorial Hospital (see separate protocols for these operating units).

** LOQ: Lowest hs-TnI concentration that is reportable as a number with specified certainty

hs-TnI: high-sensitivity troponin I

EUOSH hs-troponin I clinical protocol **INPATIENT** (not ED) – Beckman Coulter Access 2 Immunoassay analyzer [1]

Version 8/31/21



Footnotes:

1. Beckman Coulter Access 2 Immunoassay analyzer "abnormal" (>99th percentile) cut points: >11.6 mg/L (women); >19.8 ng/L (men)
2. Refers to acute findings not seen on prior ECGs, and not associated with LVH, LBBB, RBBB, or early repolarization
3. "No delta", "All deltas", or "Any delta" includes 0➔1h, 1➔3h, and 0➔3h changes in hsTnI

Chart version: August 24, 2021
Inquiries: Abhinav Goyal MD, MHS (AGOYAL4@EMORY.EDU)

MYOCARDIAL INJURY
(any hs-TnI value > 99th percentile)

No clinical evidence of overt myocardial ischemia
- No ischemic symptoms, no ECG changes, & no abnormalities on cardiac imaging

This is NOT an acute myocardial infarction (MI).

Document "NONISCHEMIC MYOCARDIAL INJURY secondary to [underlying cause]"
(outdated term: "non-MI troponin elevation")
- Treat cause of nonischemic injury (if appropriate)

Underlying causes of nonischemic myocardial injury:

Acute[1] nonischemic myocardial injury:
- Critical illness[2]
- Hypertensive emergency[2]
- Acute heart failure
- Takotsubo cardiomyopathy
- Acute pulmonary embolism (PE)
- Sepsis without shock
- Myocarditis / Pericarditis
- Acute endocarditis
- Non-cardiac surgery[2]
- Tachycardia (AFRVR, SVT, VT)[2]
- Blunt chest injury (CPR, contusion)
- Defibrillator shocks
- Cardiac ablation
- Cardiac (non-CABG) surgery
- Acute neuro event (stroke, seizure)
- Diabetic ketoacidosis
- Rhabdomyolysis
- Strenuous exercise
- Burn injuries to body

Chronic[1] nonischemic myocardial injury:
- Structural heart disease
- Severe aortic valve disease
- Hypertrophic cardiomyopathy
- Chronic pulmonary hypertension / chronic PE
- Infiltrative disease (amyloid, sarcoid, tumors, etc.)
- ESRD / advanced CKD
- Cardiotoxic agents, chemotherapy

Clinical evidence of overt myocardial ischemia
One or more of the following:
- Symptoms of acute myocardial ischemia
- New ischemic ECG changes
- New abnormality on imaging (wall motion abnormality on echo; noninvasive stress test showing ischemia or new infarct)
- Coronary angiogram / CTA show acute "culprit" lesion

This IS an acute MI.
What type of MI is it?

Identifiable precipitant causing supply-demand mismatch

Document "TYPE 2 MI secondary to [underlying precipitant]"
- Treat underlying precipitant of Type 2 MI

Underlying precipitants of Type 2 MI:

Cardiac causes:
- Tachycardia (AFRVR, SVT, VT)[2]
- Bradyarrhythmias
- Aortic dissection
- Coronary vasospasm
- Coronary vasculitis / endothelial dysfunction / microvascular disease
- Embolism to coronary artery
- Spontaneous coronary artery dissection (SCAD)

Systemic causes:
- Hypertensive emergency[2]
- Critical illness[2]
- Non-cardiac surgery[2]
- Septic shock
- Acute hypoxic resp. failure
- Severe anemia (acute blood loss, hemolysis)

Suspect acute coronary artery plaque rupture/erosion

Document "Type 1 NSTEMI" [3]
Consider:
- Cardiology consult
- Treat per NSTEMI guidelines (may include antiplatelet drugs, urgent cath)

References:
- Thygesen K et al. Fourth Universal Definition of MI (2018). J Am Card Cardiol 2018.
- Goyal A et al. What's in a name? The new ICD-10 codes and Type 2 MI. Circulation 2017;136:1180-2

1 Acute nonischemic injury is associated with a rise/fall in troponin. Chronic injury associated with "flat" troponins.
2 Some conditions may cause either a Type 2 MI or a nonischemic myocardial injury. The presence / absence of ischemic symptoms, or findings on ECG / cardiac imaging / coronary angiography may help distinguish the two.
3 The term "NSTEMI" should only be documented when referring to Type 1 NSTEMI, and not for Type 2 MI.